Literature DB >> 9688328

N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies.

D Frenkel1, M Balass, B Solomon.   

Abstract

Monoclonal antibodies 6C6 and 10D5 raised against the N-terminal of beta-amyloid peptide interfere with the formation of beta-amyloid and trigger reversal to its non-toxic components. The epitopes of these antibodies were localized employing a library composed of filamentous phage displaying random combinatorial hexapeptides. Among 44 positive phage-clones, selected from the library by both antibodies, 40 clones carried the consensus sequence EFRH. These EFRH phage-clones bind specifically mAbs 6C6 or 10D5 with an apparent binding constant of approximately 10(-9) M. The peptide EFRH inhibits binding of mAbs 6C6 or 10D5 to beta-amyloid peptide in affinities identical to those obtained. with the peptides corresponding to positions 1-9, 1-16 and 1-40 of beta-peptide. These findings confirm that the peptide EFRH which is located at positions 3-6 within beta-amyloid peptide represents the sequential epitope of mAbs 6C6 and 10D5.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688328     DOI: 10.1016/s0165-5728(98)00098-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

1.  Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.

Authors:  D Frenkel; O Katz; B Solomon
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.

Authors:  Frédérique Bard; Robin Barbour; Catherine Cannon; Robert Carretto; Michael Fox; Dora Games; Teresa Guido; Kathleen Hoenow; Kang Hu; Kelly Johnson-Wood; Karen Khan; Dora Kholodenko; Celeste Lee; Mike Lee; Ruth Motter; Minh Nguyen; Amanda Reed; Dale Schenk; Pearl Tang; Nicki Vasquez; Peter Seubert; Ted Yednock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-03       Impact factor: 11.205

3.  EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials.

Authors:  Vered Lavie; Maria Becker; Rachel Cohen-Kupiec; Iftach Yacoby; Rela Koppel; Manuela Wedenig; Birgit Hutter-Paier; Beka Solomon
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 4.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

5.  Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease.

Authors:  Maria Becker; Vered Lavie; Beka Solomon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

6.  Arginine and disordered amyloid-β peptide structures: molecular level insights into the toxicity in Alzheimer's disease.

Authors:  Orkid Coskuner; Olivia Wise-Scira
Journal:  ACS Chem Neurosci       Date:  2013-10-08       Impact factor: 4.418

7.  Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease.

Authors:  Jessica F Jordão; Carlos A Ayala-Grosso; Kelly Markham; Yuexi Huang; Rajiv Chopra; JoAnne McLaurin; Kullervo Hynynen; Isabelle Aubert
Journal:  PLoS One       Date:  2010-05-11       Impact factor: 3.240

Review 8.  Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.

Authors:  Donna M Wilcock; Carol A Colton
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

9.  Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma.

Authors:  Xiao-Han Chen; Robert Siman; Akira Iwata; David F Meaney; John Q Trojanowski; Douglas H Smith
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

Review 10.  Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.

Authors:  Donna M Wilcock; Carol A Colton
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.